Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro
International Journal of Cancer (2005) - Comments
pubmed: 15700310  doi: 10.1002/ijc.20917  issn: 0020-7136  issn: 1097-0215 

Claudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, Danilo Millimaggi, Paola Muzi, Carlo Vicentini, Mauro Bologna